Top View
- Cetuximab Preclinical Antitumor Activity
- Anti-EGFR Targeted Monoclonal Antibody Isotype Influences Antitumor Cellular Immunity in Head and Neck Cancer Patients
- HER2, a New Actionable Oncotarget in Advanced Colorectal Cancer
- View of This Manuscript
- Injectable and Health Care Administered Oncology Medical Drug Criteria Through Preferred (Optional)
- ERBITUX (Cetuximab)
- Economic Evaluation of Brentuximab Vedotin for Persistent Hodgkin Lymphoma
- Development of HER2-Targeted Therapies for Gastrointestinal Cancer
- Cetuximab and Panitumumab for Previously Untreated Metastatic Colorectal Cancer
- Tumor-Associated Hyaluronan Limits Efficacy of Monoclonal Antibody Therapy
- Antitumor Activity of Amivantamab (JNJ-61186372), an EGFR-Cmet Bispecific Antibody, In
- Combining Erlotinib and Cetuximab Is
- Determining the Effects of Trastuzumab, Cetuximab and Afatinib By
- Gastric Cancers
- Strategies for Delaying Or Treating in Vivo Acquired Resistance to Trastuzumab in Human Breast Cancer Xenografts Jeanne M
- Combination Therapy for EGFR-Mutant Lung Cancers
- Erbitux, INN-Cetuximab
- Assessment Report
- Cetuximab Combined with Chemotherapy Is Beneficial for Patients with Advanced Non-Small Cell Lung Cancer After EGFR-Tyrosine Kinase Inhibitors Failure
- Vectibix (Panitumumab) Is a Recombinant, Human Igg2 Kappa Monoclonal Antibody That Binds Specifically to the Human Epidermal Growth Factor Receptor (EGFR)
- Chemotherapy: Drugs P-Z Policy (Chemo Drug P-Z)
- The Evolution of Antibodies Into Versatile Tumor-Targeting Agents
- Oncology Comprehensive Drug List Krogerspecialtypharmacy.Com
- Table 1. Summary of Kinase Inhibitors Approved by the FDA for Treatment
- Recently Approved Therapies and Drugs in Development
- Mechanisms of Acquired Resistance to Trastuzumab Emtansine in Breast Cancer Cells
- Oncology Medications Policy (1403)
- Cetuximab) Injection, for Intravenous Use Infusion Followed by 250 Mg/M Weekly Infused Over 60 Minutes
- Dual Targeting of EGFR Can Overcome a Major Drug Resistance Mutation in Mouse Models of EGFR Mutant Lung Cancer
- Oncology Therapy for the Generalist
- Comparison of Panitumumab Plus Irinotecan and Cetuximab Plus Irinotecan for KRAS Wild-Type Metastatic Colorectal Cancer
- Antibody–Drug Conjugates
- Mechanisms of Acquired Resistance to Cetuximab: Role of HER (Erbb) Family Members
- Comparative Analysis of Drug Response and Gene Profiling Of
- Combination of Cetuximab with Chemoradiation, Trastuzumab Or MAPK Inhibitors: Mechanisms of Sensitisation of Cervical Cancer Cells
- Monoclonal Antibodies As Therapeutic Agents in Oncology and Antibody Gene Therapy
- Management of Cutaneous Side Effects of Cetuximab Therapy with Vitamin K1 Cr`Eme
- Molecular Basis for Necitumumab Inhibition of EGFR Variants
- Antitumor Activity of Amivantamab (JNJ-61186372), an EGFR–MET Bispecific Antibody, in Diverse Models of EGFR Exon 20 Insertion–Driven NSCLC
- Combined Molecular Targeted Drug Therapy for EGFR and HER-2 in Head and Neck Squamous Cell Carcinoma Cell Lines
- References I-21
- Mechanisms of Acquired Resistance to Trastuzumab Emtansine in Breast Cancer Cells Guangmin Li1, Jun Guo1, Ben-Quan Shen2, Daniela Bumbaca Yadav2, Mark X
- Safety of Ramucirumab Regimen Without H1-Antihistamine
- Standard Oncology Criteria Policy Number: Pending
- Biomarker-Guided Anti-Egfr Rechallenge Therapy in Metastatic Colorectal Cancer
- Corporate Medical Policy Panitumumab (Vectibix®)
- Pharmacokinetics of Therapeutic Monoclonal Antibodies Used in Oncology
- Global Oncology
- Panitumumab and Cetuximab Toxicity Management Guidelines
- Precision Cancer Therapy
- Smart Approaches for the Effective Treatment of Breast Cancer
- Phase I Study of Olaratumab in Japanese Patients with Advanced Solid Tumors
- 125547Orig1s000
- A Nationwide Study on the Impact of Routine Testing for EGFR Mutations in Advanced NSCLC Reveals Distinct Survival Patterns Based on EGFR Mutation Subclasses
- Ramucirumab: Successfully Targeting Angiogenesis in Gastric Cancer
- 5.01.603 Epidermal Growth Factor Receptor (EGFR) Inhibitors
- Monoclonal Antibodies in Cancer Therapy
- Precision Oncology Drug Approvals in 2020 - New Drugs and Expanded Indications
- Lilly Announces Details of Presentations at 2021 American Society of Clinical Oncology (ASCO) Annual Meeting
- Olaratumab in Combination with Doxorubicin for Treatment Of
- Multiplex LCMS Bioanalysis of Brentuximab Vedotin, Rituximab
- Ramucirumab in the Second-Line Treatment of Metastatic Colorectal Cancer: a Narrative Review of Literature from Clinical Trials
- Cetuximab (Erbitux)
- A Novel Bispecific Antibody Targeting EGFR and VEGFR2 Is Effective Against Triple Negative Breast Cancer Via Multiple Mechanisms
- Therapeutic Application of Monoclonal Antibodies in Pancreatic Cancer: Advances, Challenges and Future Opportunities
- HER2-Overexpressing/Amplified Breast Cancer As a Testing Ground for Antibody-Drug Conjugate Drug Development in Solid Tumors
- Erbitux, INN-Cetuximab
- Olaratumab for STS Disappoints in Phase III
- A Review of the Evidence for Occupational Exposure Risks To
- Systemic Therapy Update
- Anti-Tubulin Drugs Conjugated to Anti-Erbb Antibodies Selectively Radiosensitize
- The Tale of HER2